Treating Waldenstrom’s Macroglobulinemia

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Asher Chanan-Khan about current standards of care for Waldenstrom macroglobulinemia, as well as a clinical trial looking at a novel therapy.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Asher Chanan-Khan about the current standards of care for Waldenstrom macroglobulinemia, also known as WM.

WM is a rare, incurable disease. Its current standards of care available consist of Rituxan (rituximab), Imbruvica (ibrutinib) combinations or monotherapy in the first- and second-line setting. However, there are no treatments currently approved for the third line.

Chanan-Khan discussed these options, as well as a novel agent, CLR 131, that is being evaluated in a phase 2 study.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.